Announcement: “At SSDP, we believe in the importance of psychedelic research. That’s why we’re taking the DEA to court!”

The DEA wants to add two important research chemicals—2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC)—to Schedule I of the Controlled Substances Act, despite decades of safe usage in labs and no history of abuse. DOI and DOC’s current status as unscheduled compounds has made them de facto tools for researchers studying serotonin receptors. They have featured in […]